Vertex Pharmaceuticals Incorporated

États‑Unis d’Amérique


 
Quantité totale PI 1 585
Quantité totale incluant filiales 1 609 (+ 24 pour les filiales)
Rang # Quantité totale PI 830
Note d'activité PI 3,6/5.0    734
Rang # Activité PI 977
Activité incl filiales 3,2/5.0    740
Symbole boursier
ISIN US92532F1003
Capitalisation 118,999M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

634 82
186 65
527 39
52
 
Dernier brevet 2025 - Materials and methods for treatm...
Premier brevet 1990 - Immunosuppressive compounds
Dernière marque 2025 - POWER FORWARD
Première marque 1989 - VERTEX

Filiales

5 subsidiaries with IP (24 patents, 0 trademarks)

6 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Providing health information to patients and caregivers; providing health care information; provi...
P/S Providing medical information, namely, consumer product information regarding medical products to...
P/S Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, be...
P/S Providing health information to patients, caregivers and health care professionals; providing hea...
2024 Invention Crystalline forms of c21h22cl2n4o2. The present invention provides crystalline forms of a compou...
Invention Compounds for the treatment of kidney disease. The disclosure provides polycystin-1 (PC1) correct...
Invention Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof. Provi...
Invention Heteroaryl compounds for the treatment of pain. Compounds, and pharmaceutically acceptable salts ...
Invention Methods of preparing modulators of sodium channels and solid forms of the same for treating pain....
Invention Methods of preparing compounds for treating pain and solid forms thereof. Processes for preparing...
Invention Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver. C...
P/S Pharmaceutical preparations for the treatment of cystic fibrosis.
P/S Pharmaceutical preparations for the treatment of cystic fibrosis.
Invention Solid forms of modulators of cystic fibrosis transmembrane conductance regulator. Crystalline for...
Invention Modulators of cystic fibrosis transmembrane conductance regulator. This disclosure provides modul...
Invention Differentiation of pancreatic endocrine cells. Disclosed herein are compositions and methods rel...
P/S Pharmaceutical preparations for the treatment of cystic fibrosis
Invention Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluorome...
Invention Complement factor i-related compositions and methods. Provided herein are Complement Factor I (C...
Invention Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy...
Invention Precise excisions of portions of exons for treatment of duchenne muscular dystrophy. Composition...
Invention Differentiation of pancreatic endocrine cells. Disclosed herein are compositions and methods rela...
Invention Cell therapy for diabetes. Disclosed herein are methods of treating a subject having diabetes wi...
Invention Cell therapy for diabetes. Disclosed herein are methods of treating a subject having diabetes wit...
Invention Macroencapsulation device implantation and transport system and methods. Macroencapsulation impl...
Invention Gcn2 inhibitors and uses thereof. The present invention provides compounds, compositions thereof...
Invention Materials and methods for treatment of human genetic diseases including hemoglobinopathies. The ...
Invention Urea-containing agonists of orexin receptor type 2. Disclosed are compounds, compositions, and me...
Invention Materials and methods for treatment of duchenne muscular dystrophy. The present application prov...
Invention Complement factor-i formulations. Provided herein are pharmaceutically acceptable formulations c...
Invention Inhibitors of apol1 and methods of using same. The disclosure provides at least one entity chose...
Invention Affinity purification methods for adeno associated viruses (aavs). Provided herein are isolated p...
Invention Methods for directing lipid nanoparticles in vivo. Compositions and methods for enhancing payload...
Invention Compact proteins. Disclosed herein are compositions of compact proteins such as compact nucleobas...
Invention Stem cell derived pancreatic islet differentiation. Disclosed herein are compositions and method...
Invention Pharmaceutical compositions for treating cystic fibrosis. A pharmaceutical composition comprisin...
P/S Educational services, namely, providing classes, seminars, and workshops in the fields of medicat...
Invention Islet cell manufacturing compositions and methods of use. Disclosed herein are compositions and ...
Invention Gene editing of regulatory elements. Compositions and methods for disrupting and/or excising reg...
P/S Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, b...
2023 P/S Pharmaceuticals and medical treatment products in the field of diabetes; cell therapy products fo...
P/S Pharmaceuticals and medical treatments in the field of diabetes; cell therapy products for medica...
P/S Pharmaceuticals and medical treatments in the field of diabetes; cell therapy products for medic...
P/S Pharmaceuticals and medical treatment products in the field of diabetes; cell therapy products f...
P/S Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diabe...
P/S Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diab...
Invention Substituted tetrahydrofurans as modulators of sodium channels. Compounds, and pharmaceutically ac...
Invention Crystalline forms of cftr modulators. Crystalline forms of Compound I: Crystalline forms of Co...
Invention Modulators of alpha-1 antitrypsin. The disclosure provides compounds useful for treating alpha-1...
Invention Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, m...
P/S medical and scientific research; medical and scientific research in the field of gene therapy; me...
Invention Cell housing device. The present disclosure provides a cell housing device and a method of manuf...
P/S Providing on-line non-downloadable software for use by healthcare professionals to view and acces...
P/S Providing health information in the field of sickle cell disease; providing health care informati...
Invention 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and met...
Invention Modulators of cystic fibrosis transmembrane conductance regulator. This disclosure provides modu...
2022 Invention Stem cell differentiation and chemical compounds. Disclosed herein are compositions and methods ...
Invention Macroencapsulation devices. Macroencapsulation devices and related methods of manufacture are de...
Invention N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channel...
Invention Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels. Compounds of formul...
Invention Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels. Compound...
Invention Stem cell differentiation and polymers. Disclosed herein are compositions and methods related to...
2021 Invention Enhanced differentiation of beta cells. Provided herein are, inter alia, compositions and method...